This, of course, is a possibility. There is also the possibility that common shares survive.
There have been some reasonable points made in regards to BioAmber shareholders receiving nothing in terms of equity claims, however, very little has been said or supported with facts in terms of equity interest ending up with nothing.
At a glance, there appears to be a lot of uncertainty at the moment. The unusual thing when it comes to BioAmber is that there seems to be little to zero uncertainty at the extremes, namely that shares will either be cancelled or survive and thrive.
